N-Krypt

NKrypt is a preclinical-stage biotechnology company focused on developing next-generation Natural Killer (NK) cell therapies for oncology. Based in Oslo, Norway, the company utilizes a proprietary engineering platform to enhance the persistence, homing, and potency of NK cells within the challenging immunosuppressive environment of solid tumors. NKrypt's approach involves genetic modifications designed to optimize NK cell fitness and effector function, aiming to provide more effective "off-the-shelf" treatment options for cancer patients. The company was founded by world-leading experts in NK cell biology and is supported by specialized life science venture capital.